Yupelri is a brand name for the inhaled medication revealed. The active ingredient is revefenacin [1]. Revefenacin is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1][2]. It works by relaxing the muscles in the airways, making it easier to breathe [1].
How long does Yupelri stay in the system?
The elimination half-life of revefenacin, the active ingredient in Yupelri, is approximately 56 hours in patients with COPD. This means it takes about 56 hours for the concentration of the drug in the body to reduce by half [1].
When does Yupelri's patent expire?
Information regarding the specific patent expiration dates for Yupelri (revefenacin) can be found on patent tracking websites [3]. For instance, DrugPatentWatch.com provides a database of drug patents and their expiry timelines [3].
Who makes Yupelri?
Yupelri was developed by Mylan and Theravance Biopharma [4]. It is currently marketed by Covis Pharma [5].
How does Yupelri compare to other COPD treatments?
As a LAMA, Yupelri works by widening the airways. Other classes of COPD medications include short-acting muscarinic antagonists (SAMAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), and combination therapies. The choice of treatment depends on the severity of the COPD and individual patient needs. For example, LAMAs like Yupelri are typically used for long-term symptom management [1][6].
What are the potential side effects of Yupelri?
Common side effects reported with Yupelri include upper respiratory tract infection, bronchitis, and back pain [1]. As with all medications, patients may experience other side effects. It is important to discuss any concerns with a healthcare provider [1].
Can Yupelri be used for acute asthma attacks?
Yupelri is indicated for the maintenance treatment of COPD and is not intended for the relief of acute bronchospasm or asthma attacks [1][2].
How is Yupelri administered?
Yupelri is administered as an inhalation. It is used with a specific nebulizer device [1].
What is the clinical data supporting Yupelri's use?
Clinical trials have demonstrated that Yupelri improves lung function in patients with COPD. Studies have shown statistically significant improvements in trough forced expiratory volume in one second (FEV1) compared to placebo when administered once daily [1].
What is the pricing and insurance coverage for Yupelri?
Pricing and insurance coverage for Yupelri can vary. Patients are often advised to check with their insurance providers or use manufacturer discount programs for potential cost savings [7].
Where can I find more information on Yupelri patents and exclusivity?
Detailed information on Yupelri's patent status, including expiration dates and any potential exclusivity periods, is available through specialized pharmaceutical patent databases, such as DrugPatentWatch.com [3].
---
Sources:
[1] https://www.yupepri.com/
[2] https://www.rxlist.com/yuplri-drug.htm
[3] https://www.drugpatentwatch.com/
[4] https://www.fiercepharmamanagement.com/drugs/mylan-theravance-co-announce-approval-yuplri-copd
[5] https://www.biospace.com/article/releases/covis-pharma-acquires-yuplri-revefenacin-from-mylan-and-theravance-biopharma/
[6] https://www.goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-report-final-wms.pdf
[7] https://www.goodrx.com/yuplri